Informations générales (source: ClinicalTrials.gov)

NCT03017573 En recrutement IDF
Prospective Biobanking Study in Ovarian, Breast, Head and Neck and Cervical Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) (SCANDARE)
Interventional
  • Tumeurs du col de l'utérus
  • Tumeurs de la tête et du cou
  • Tumeurs du sein triple-négatives
N/A
Institut Curie (Voir sur ClinicalTrials)
janvier 2017
janvier 2031
29 juin 2024
SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples at different time points in ovarian, triple negative breast, Head and Neck Cancer and Cervical cancer patients. This study will allowed to identify new molecular and/or immunological biomarkers associated with clinical and biological features of the tumors. All patients will receive standard treatment according to the stage of the diseases and usual procédures.
 Voir le détail

Etablissements

Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données
CLCC INSTITUT CURIE En recrutement IDF 04/12/2024 12:44:25  Contacter
CLCC RENE HUGUENIN INSTITUT CURIE En recrutement IDF 04/12/2024 12:44:08  Contacter
Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Centre Leon Berard - 69373 - Lyon - France Nicolas CHOPIN, MD Recrutement non commencé Contact (sur clinicalTrials)
Centre Oscar Lambret - 59000 - Lille - France Camille PASQUESOONE, MD En recrutement Contact (sur clinicalTrials)
Institut Bergonie - 33076 - Bordeaux - France Adeline PETIT, MD Recrutement non commencé Contact (sur clinicalTrials)

Critères

Tous
Inclusion Criteria:

1. Tumor types :

1. Newly diagnosed treatment-naïve ovarian cancer patients eligible for surgery or
neoadjuvant chemotherapy

2. Newly diagnosed treatment-naïve triple-negative breast cancer patients eligible
for surgery or neoadjuvant chemotherapy

3. Newly diagnosed treatment-naïve head and neck cancer patients eligible for
surgery

4. Newly diagnosed treatment-naïve cervical cancer patients (1) stage Ia - IIa1
with nodal metastasis, postoperative positive margin or parametrial-vaginal
involvement, and (2) stage ≥IIa2).

2. Male or female patients ≥ 18 years of age

3. Signed informed consent


1. Male or female patients ≤18 years old

2. Patients with any psychological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule

3. Individually deprived of liberty or placed under the authority of a tutor

4. Patients not affiliated to the Social Security System